Vistagen Therapeutics, Inc. annual report, FY2016

Business context and reporting period

VistaGen Therapeutics, Inc. filed this Form 10-K for the fiscal year ended March 31, 2016, with fiscal 2015 as the comparable year. Although the request labels the period “2015 Q4,” this is an annual report, not a standalone quarterly filing; it includes unaudited quarterly results. VistaGen is a clinical-stage biopharmaceutical company with no approved products or product-sale revenue. Its lead candidate, oral AV-101, was in Phase 2 development for major depressive disorder (MDD). The company also pursued stem-cell-based drug-rescue and regenerative-medicine opportunities.

Financial results and liquidity

Metric	FY ended Mar. 31, 2016	FY ended Mar. 31, 2015
Revenue	$0	$0
Research and development expense	$3.93 million	$2.43 million
General and administrative expense	$13.92 million	$4.34 million
Operating loss	$17.85 million	$6.78 million
Net loss	$47.22 million	$13.89 million
Net loss attributable to common stockholders	$51.42 million	$13.89 million
Basic loss per share	$29.08	$10.53
Cash used in operating activities	$4.81 million	$2.77 million
Cash and cash equivalents at year-end	$428,500	$70,000

Margins are not meaningful because the company reported no revenue. The FY2016 net loss included $26.70 million of loss on extinguishment of debt and $1.89 million of warrant-liability expense; these were principally noncash accounting charges. Operating expenses also included substantial noncash stock compensation and warrant-modification expense. Cash used in operations was substantially below net loss, reflecting these and other noncash items.

At March 31, 2016, current assets were $855,300 and current liabilities were $1.79 million, a working-capital deficit of approximately $939,400. Total liabilities were $3.97 million, including $58,800 of notes payable and $2.09 million of accrued Series B preferred dividends. The company reported a $131.7 million accumulated deficit. It converted approximately $17.2 million of debt into Series B preferred stock and related securities during FY2016, sharply reducing recorded debt but creating significant dilution and preferred-stock obligations.

Subsequent to year-end, VistaGen raised $278,000 through additional Series B preferred units and completed a May 2016 public offering with approximately $9.5 million in net proceeds. Management said these funds were expected to support operations through FY2017, but not to complete the planned Phase 2b study. Without substantial warrant proceeds, the company estimated it would need another $10–12 million before the end of Q2 2017 to complete that study. A $71,600 note was repaid in June 2016; the filing says no promissory notes remained after that payment.

Material changes versus the prior year

• Net loss more than tripled, driven largely by debt-extinguishment accounting charges following the conversion of debt into preferred equity, as well as higher operating expenses.
• R&D expense increased 62%, reflecting higher AV-101 development and patent costs, among other items. G&A expense rose substantially, including warrant modifications, stock-based compensation and professional fees.
• Interest expense declined to $771,000 from $4.55 million as substantial promissory-note balances were converted into preferred stock.
• Operating cash use increased to $4.81 million from $2.77 million. Financing activities provided $5.19 million, primarily from Series B preferred-unit sales.
• The company entered an NIH/NIMH agreement under which the NIMH funded and conducted the AV-101 Phase 2a MDD study; first patient dosing occurred in November 2015.

Outlook, management commentary and risks

• Management anticipated Phase 2a topline results in Q2 2017 and a Phase 2b MDD study launch in Q4 2016, with approximately 325 patients and topline results expected in Q2 2018. These are forward-looking estimates, not guarantees.
• Management estimated AV-101 might be ready for commercialization in 2021, subject to successful clinical development and regulatory approval. The filing provides no near-term revenue guidance.
• The Phase 2a study was NIMH-funded; VistaGen expected to fund the larger Phase 2b program itself or obtain additional financing. The filing identifies financing availability and going-concern capacity as central risks.
• AV-101 had not yet demonstrated efficacy in the ongoing Phase 2a study. Earlier preclinical and Phase 1 safety findings do not establish later-stage efficacy or safety. Trial delays, enrollment, manufacturing, regulatory requirements, and adverse events could increase costs or impede development.
• VistaGen depended on third-party manufacturers, CROs, and clinical collaborators and had no commercial sales infrastructure. Competition, reimbursement and market acceptance could limit eventual commercial prospects.
• AV-101 itself was not patented, and relevant previously licensed patent rights had expired. The company was pursuing formulation, method-of-use and synthesis patents, but issuance and scope were uncertain. Patent protection and potential intellectual-property claims remain material risks.
• The May 2016 offering and outstanding preferred shares, warrants and options create potential dilution. The company also disclosed a thin historical trading market, concentrated ownership and possible stock-price volatility.
• The independent auditor issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-controls attestation.

Important facts for investors to verify

1. Confirm the precise period: the filing covers the fiscal year ended March 31, 2016, despite the request’s “2015 Q4” label.
2. Track actual Phase 2a results and Phase 2b launch, enrollment, costs and timing against management’s estimates.
3. Assess the company’s cash runway, subsequent cash burn, warrant exercises and whether additional financing was secured on acceptable terms.
4. Review the terms, conversion and dividend features, and dilution implications of Series B and Series C preferred stock and outstanding warrants.
5. Evaluate the composition of the reported loss, especially noncash debt-extinguishment, warrant-modification and stock-compensation charges.
6. Check patent prosecution outcomes and the strength of AV-101’s potential commercial exclusivity.